CHEN Wei,CHEN Jiayi,LI Ling,et al.Meta-analysis of the efficacy and safety of immune checkpoint inhibitors in the treatment of metastatic colorectal cancer[J].ZHONGGUO YAOFANG,2023,34(04):482-486.
CHEN Wei,CHEN Jiayi,LI Ling,et al.Meta-analysis of the efficacy and safety of immune checkpoint inhibitors in the treatment of metastatic colorectal cancer[J].ZHONGGUO YAOFANG,2023,34(04):482-486. DOI: 10.6039/j.issn.1001-0408.2023.04.19.
Meta-analysis of the efficacy and safety of immune checkpoint inhibitors in the treatment of metastatic colorectal cancer
To systematically evaluate the efficacy and safety of immune checkpoint inhibitors (ICIs) in the treatment of metastatic colorectal cancer (mCRC), so as to provide evidence-based reference for clinical practice.
METHODS
2
PubMed, the Cochrane Library, Web of Science, Embase, CNKI, Wanfang and VIP databases were searched to collect randomized controlled trials (RCT) of ICIs (trial group) versus traditional chemotherapy or optimal supportive treatment (control group) in the treatment of mCRC from the establishment of the database to June 1, 2022. After literature screening and data extraction, Cochrane Systematic Review Manual 5.1.0 was used to evaluate the quality of the included literature, and RevMan 5.4 software was used for meta-analysis and sensitivity analysis.
RESULTS
2
A total of 4 RCTs were included, involving 833 patients. Meta-analysis showed that the overall survival (OS) [HR=0.77, 95%CI (0.64, 0.94),
P
=0.01] and progression-free survival (PFS) [HR=0.67, 95%CI (0.57, 0.79),
P
<0.000 01] were significantly higher in trial group than control group; the difference was not statistically significant when comparing the incidence of grade 3 and above adverse events in the two groups [RR=1.22, 95%CI (0.77, 1.94),
P
=0.39]. Subgroup analysis by mutation pattern showed that patients with mismatch repair proficiency and low levels of microsatellite instability (pMMR-MSS) mCRC patients in trial group had significantly higher PFS than control group (
P
<0.05). The results of sensitivity analysis showed that the results were robust.
CONCLUSIONS
2
Compared with traditional chemotherapy or optimal supportive treatment, ICIs can prolong the OS and PFS of mCRC patients, and maybe has more advantages in pMMR-MSS mCRC patients; the safety of ICIs is equivalent to that of traditional chemotherapy or optimal supportive treatment.
SUNG H,FERLAY J,SIEGEL R L,et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3):209-249.
BILLER L H,SCHRAG D. Diagnosis and treatment of metastatic colorectal cancer:a review[J]. JAMA,2021,325(7):669-685.
VAN DER STOK E P,SPAANDER M C W,GRÜNHAGEN D J,et al. Surveillance after curative treatment for colorectal cancer[J]. Nat Rev Clin Oncol,2017,14(5):297-315.
MESSERSMITH W A. NCCN guidelines updates: management of metastatic colorectal cancer[J]. J Natl Compr Canc Netw,2019,17(5.5):599-601.
TOPALIAN S L,HODI F S,BRAHMER J R,et al. Safety,activity,and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med,2012,366(26):2443-2454.
HUDSON K,CROSS N,JORDAN-MAHY N,et al. The extrinsic and intrinsic roles of PD-L1 and its receptor PD-1:implications for immunotherapy treatment[J]. Front Immunol,2020,11:568931.
TOPALIAN S L,DRAKE C G,PARDOLL D M. Targeting the PD-1/B7-H1(PD-L1)pathway to activate anti-tumor immunity[J]. Curr Opin Immunol,2012,24(2):207-212.
JOHDI N A,SUKOR N F. Colorectal cancer immunotherapy:options and strategies[J]. Front Immunol,2020,11:1624.
CANTERO-CID R,CASAS-MARTIN J,HERNÁNDEZ-JIMÉNEZ E,et al. PD-L1/PD-1 crosstalk in colorectal cancer:are we targeting the right cells?[J]. BMC Cancer,2018,18(1):945.
LOCHHEAD P,KUCHIBA A,IMAMURA Y,et al. Mi-crosatellite instability and BRAF mutation testing in colorectal cancer prognostication[J]. J Natl Cancer Inst,2013,105(15):1151-1156.
OVERMAN M J,LONARDI S,WONG K Y M,et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer[J]. J Clin Oncol,2018,36(8):773-779.
ANDRÉ T,SHIU K K,KIM T W,et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer[J]. N Engl J Med,2020,383(23):2207-2218.
BENSON A B,VENOOK A P,AL-HAWARY M M,et al. Colon cancer,version 2.2021,NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw,2021,19(3):329-359.
ENG C,KIM T W,BENDELL J,et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer(IMblaze370):a multicentre,open-label,phase 3,randomised,controlled trial[J]. Lancet Oncol,2019,20(6):849-861.
OVERMAN M J,MCDERMOTT R,LEACH J L,et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer(CheckMate 142):an open-label,multicentre,phase 2 study[J]. Lancet Oncol,2017,18(9):1182-1191.
EISENHAUER E A,THERASSE P,BOGAERTS J,et al. New response evaluation criteria in solid tumours:revised RECIST guideline:version 1.1[J]. Eur J Cancer,2009,45(2):228-247.
PANIC N,LEONCINI E,DE BELVIS G,et al. Evaluation of the endorsement of the preferred reporting items for systematic reviews and meta-analysis(PRISMA)statement on the quality of published systematic review and meta-analyses[J]. PLoS One,2013,8(12):e83138.
GREEN S,HIGGINS J P. Preparing a cochrane review[M]//Cochrane Handbook for Systematic Reviews of Interventions. Chichester,UK:John Wiley & Sons,Ltd.,2008:11-30.
CHEN E X,JONKER D J,LOREE J M,et al. Effect of combined immune checkpoint inhibition vs best suppor-tive care alone in patients with advanced colorectal cancer:the Canadian cancer trials group CO.26 study[J]. JAMA Oncol,2020,6(6):831-838.
CREMOLINI C,ROSSINI D,ANTONIOTTI C,et al. LBA20 FOLFOXIRI plus bevacizumab(bev)plus atezolizumab(atezo)versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer(mCRC)patients:results of the phase Ⅱ randomized AtezoTRIBE study by GONO[J]. Ann Oncol,2021,32:S1294-S1295.
METTU N B,OU F S,ZEMLA T J,et al. Assessment of capecitabine and bevacizumab with or without atezolizumab for the treatment of refractory metastatic colorectal cancer:a randomized clinical trial[J]. JAMA Netw Open,2022,5(2):e2149040.
LE D T,URAM J N,WANG H,et al. PD-1 blockade in tumors with mismatch-repair deficiency[J]. N Engl J Med,2015,372(26):2509-2520.
BRAHMER J R,TYKODI S S,CHOW L Q,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer[J]. N Engl J Med,2012,366(26):2455-2465.
BASILE D,GARATTINI S K,BONOTTO M,et al. Immunotherapy for colorectal cancer:where are we hea-ding?[J]. Expert Opin Biol Ther,2017,17(6):709-721.
SHARMA P,HU-LIESKOVAN S,WARGO J A,et al. Primary,adaptive,and acquired resistance to cancer immunotherapy[J]. Cell,2017,168(4):707-723.
LE D T,HUBBARD-LUCEY V M,MORSE M A,et al. A blueprint to advance colorectal cancer immunotherapies[J]. Cancer Immunol Res,2017,5(11):942-949.
NETWORK C G A. Comprehensive molecular characteri-zation of human colon and rectal cancer[J]. Nature,2012,487(7407):330-337.
VOGELSTEIN B,PAPADOPOULOS N,VELCULESCU V E,et al. Cancer genome landscapes[J]. Science,2013,339(6127):1546-1558.
BROWNING M,PETRONZELLI F,BICKNELL D,et al. Mechanisms of loss of HLA class Ⅰ expression on colorectal tumor cells[J]. Tissue Antigens,1996,47(5):364-371.
GRASSO C S,GIANNAKIS M,WELLS D K,et al. Genetic mechanisms of immune evasion in colorectal cancer[J]. Cancer Discov,2018,8(6):730-749.
PAI S G,CARNEIRO B A,MOTA J M,et al. Wnt/beta-catenin pathway:modulating anticancer immune response[J]. J Hematol Oncol,2017,10(1):101.
LEE J J,CHU E. Recent advances in the clinical development of immune checkpoint blockade therapy for mismatch repair proficient(pMMR)/non-MSI-H metastatic colorectal cancer[J]. Clin Colorectal Cancer,2018,17(4):258-273.
Network meta-analysis for efficacy and safety of TACE combined with local ablation in the treatment of unresectable primary liver cancer
Clinical observation of tofacitinib combined with hydroxychloroquine in the treatment of refractory rheumatoid arthritis
Meta-analysis of efficacy and safety of sedative therapy with midazolam and dexmedetomidine/propofol in critically ill patients undergoing mechanical ventilation
Efficacy and safety of tyrosine kinase inhibitors in the treatment of HER2-positive breast cancer: a meta-analysis
Efficacy and safety of domestic Paliperidone extended-release tablets in the treatment of stable schizophrenia
Related Author
TIAN Yuan
TANG Guiju
LI Bo
LI Yaling
WANG Mingjie
XU Fengjin
ZHANG Yan
XUE Yan
Related Institution
Dept. of Pharmacy, Zigong Fourth People’s Hospital
Dept. of Pharmacy, the Affiliated Hospital of Southwest Medical University
Dept. of Pharmacy, Ziyang Municipal First People’s Hospital
Dept. of Hepatobiliary Surgery, the Affiliated Hospital of Southwest Medical University
Dept. of General Medicine, Hengshui Municipal People’s Hospital